title: Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.
abstract: Traditionally, vaccines have been utilized to generate immune responses to a pathogen in a naive population. In the setting of congenital cytomegalovirus (CMV) infection, a vaccine that, when administered to women already infected with CMV, could boost the mother's immunity to CMV would most likely be beneficial in diminishing in utero transmission of CMV. However, the ability to boost an immune response in a population of individuals seropositive for a pathogen of interest is not well studied. This study examines the ability of a recombinant CMV glycoprotein B vaccine with MF59 adjuvant to boost both antibody (neutralizing and enzyme-linked immunosorbent assay end point dilution titer) and CD4+ T-cell responses in previously CMV-seropositive women by way of natural infection. These data suggest that this vaccine is capable of boosting immunity in a population of CMV-infected women and warrants additional evaluation to determine whether these boosted responses may prevent mother to child transmission of CMV.
authors: Department of Medicine, University of Alabama at Birmingham, AL 35294, USA. sabbaj@uab.edu
authors: Steffanie
authors: S
authors: Sabbaj
authors: Robert F
authors: RF
authors: Pass
authors: Paul A
authors: PA
authors: Goepfert
authors: Sylvie
authors: S
authors: Pichon
references: J Exp Med. 2002 Jun 17;195(12):1541-8
references: 12070282
references: J Exp Med. 2003 Dec 15;198(12):1807-15
references: 14676295
references: JAMA. 2003 Feb 26;289(8):1008-11
references: 12597753
references: J Clin Invest. 2000 Feb;105(4):541-8
references: 10683384
references: J Infect Dis. 2007 Jan 1;195(1):108-17
references: 17152014
references: Nat Med. 2005 Oct;11(10):1113-7
references: 16186817
references: Nat Immunol. 2000 Nov;1(5):426-32
references: 11062503
references: Annu Rev Immunol. 2004;22:711-43
references: 15032594
references: Nat Immunol. 2003 Jul;4(7):680-6
references: 12808452
references: N Engl J Med. 2009 Mar 19;360(12):1191-9
references: 19297572
references: J Virol. 2008 Jul;82(13):6458-69
references: 18448544
references: J Virol. 2002 Mar;76(5):2298-305
references: 11836408
references: Eur J Immunol. 2004 Dec;34(12):3525-33
references: 15484193
references: Science. 2010 Apr 2;328(5974):102-6
references: 20360110
references: Eur J Immunol. 2008 Jan;38(1):273-82
references: 18081039
references: J Virol Methods. 1986 Aug;14(1):37-41
references: 3021795
references: Blood. 2003 Apr 1;101(7):2686-92
references: 12411292
references: Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9357-62
references: 15197277
references: Nat Med. 2005 Oct;11(10):1118-24
references: 16186818
references: Eur J Immunol. 2007 Apr;37(4):1129-38
references: 17372991
references: J Exp Med. 2003 Dec 15;198(12):1797-806
references: 14662907
references: J Virol. 2007 Aug;81(16):8468-76
references: 17553885
references: N Engl J Med. 2001 May 3;344(18):1366-71
references: 11333993
references: J Infect Dis. 2008 Mar 15;197(6):825-35
references: 18419349
references: J Infect Dis. 2004 Apr 15;189(8):1374-81
references: 15073673
references: Vaccine. 2008 Jun 19;26(26):3209-22
references: 18462843
references: N Engl J Med. 1980 Oct 23;303(17):958-62
references: 6251370
references: J Infect Dis. 2011 Mar 1;203(5):610-9
references: 21282192
references: J Exp Med. 2006 Dec 25;203(13):2865-77
references: 17158960
references: J Exp Med. 2007 Jan 22;204(1):79-91
references: 17190839
references: J Infect Dis. 2003 Dec 15;188(12):1868-74
references: 14673766
references: Eur J Immunol. 1994 Feb;24(2):330-5
references: 7507843